These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 8236160)

  • 1. Antithrombotic activity of recombinant tick anticoagulant peptide and heparin in a rabbit model of venous thrombosis.
    Fioravanti C; Burkholder D; Francis B; Siegl PK; Gibson RE
    Thromb Res; 1993 Aug; 71(4):317-24. PubMed ID: 8236160
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antithrombotic efficacy of recombinant tick anticoagulant peptide. A potent inhibitor of coagulation factor Xa in a primate model of arterial thrombosis.
    Schaffer LW; Davidson JT; Vlasuk GP; Siegl PK
    Circulation; 1991 Oct; 84(4):1741-8. PubMed ID: 1833089
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conjunctive enhancement of enzymatic thrombolysis and prevention of thrombotic reocclusion with the selective factor Xa inhibitor, tick anticoagulant peptide. Comparison to hirudin and heparin in a canine model of acute coronary artery thrombosis.
    Sitko GR; Ramjit DR; Stabilito II; Lehman D; Lynch JJ; Vlasuk GP
    Circulation; 1992 Feb; 85(2):805-15. PubMed ID: 1735171
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antithrombotic actions of selective inhibitors of blood coagulation factor Xa in rat models of thrombosis.
    Wong PC; Crain EJ; Nguan O; Watson CA; Racanelli A
    Thromb Res; 1996 Jul; 83(2):117-26. PubMed ID: 8837310
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of sustained antithrombotic effects of inhibitors of thrombin and factor Xa in experimental thrombosis.
    Biemond BJ; Friederich PW; Levi M; Vlasuk GP; Büller HR; ten Cate JW
    Circulation; 1996 Jan; 93(1):153-60. PubMed ID: 8616922
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antithrombotic and hemostatic capacity of factor Xa versus thrombin inhibitors in models of venous and arteriovenous thrombosis.
    Sinha U; Ku P; Malinowski J; Zhu BY; Scarborough RM; Marlowe CK; Wong PW; Lin PH; Hollenbach SJ
    Eur J Pharmacol; 2000 Apr; 395(1):51-9. PubMed ID: 10781674
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the in vivo anticoagulant properties of standard heparin and the highly selective factor Xa inhibitors antistasin and tick anticoagulant peptide (TAP) in a rabbit model of venous thrombosis.
    Vlasuk GP; Ramjit D; Fujita T; Dunwiddie CT; Nutt EM; Smith DE; Shebuski RJ
    Thromb Haemost; 1991 Mar; 65(3):257-62. PubMed ID: 2048051
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The comparative effects of recombinant hirudin (CGP 39393) and standard heparin on thrombus growth in rabbits.
    Agnelli G; Pascucci C; Cosmi B; Nenci GG
    Thromb Haemost; 1990 Apr; 63(2):204-7. PubMed ID: 2363121
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterisation of a novel series of aprotinin-derived anticoagulants. II. Comparative antithrombotic effects on primary thrombus formation in vivo.
    Stassen JM; Lambeir AM; Vreys I; Deckmyn H; Matthyssens G; Nyström A; Vermylen J
    Thromb Haemost; 1995 Aug; 74(2):655-9. PubMed ID: 8585002
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sustained antithrombotic activity of hirudin after its plasma clearance: comparison with heparin.
    Agnelli G; Renga C; Weitz JI; Nenci GG; Hirsh J
    Blood; 1992 Aug; 80(4):960-5. PubMed ID: 1498336
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of enoxaparin, hirulog, and heparin as adjunctive antithrombotic therapy during thrombolysis with rtPA in the stenosed canine coronary artery.
    Leadley RJ; Kasiewski CJ; Bostwick JS; Bentley R; McVey MJ; White FJ; Perrone MH; Dunwiddie CT
    Thromb Haemost; 1997 Oct; 78(4):1278-85. PubMed ID: 9364998
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Maintenance of canine coronary artery patency following thrombolysis with front loaded plus low dose maintenance conjunctive therapy. A comparison of factor Xa versus thrombin inhibition.
    Lynch JJ; Sitko GR; Mellott MJ; Nutt EM; Lehman ED; Friedman PA; Dunwiddie CT; Vlasuk GP
    Cardiovasc Res; 1994 Jan; 28(1):78-85. PubMed ID: 8111795
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Specific factor Xa inhibition reduces restenosis after balloon angioplasty of atherosclerotic femoral arteries in rabbits.
    Ragosta M; Gimple LW; Gertz SD; Dunwiddie CT; Vlasuk GP; Haber HL; Powers ER; Roberts WC; Sarembock IJ
    Circulation; 1994 Mar; 89(3):1262-71. PubMed ID: 8124815
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of selective factor Xa inhibition on arterial thrombus formation triggered by tissue factor/factor VIIa or collagen in an ex vivo model of shear-dependent human thrombogenesis.
    Orvim U; Barstad RM; Vlasuk GP; Sakariassen KS
    Arterioscler Thromb Vasc Biol; 1995 Dec; 15(12):2188-94. PubMed ID: 7489241
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Additive effect of the combined administration of low molecular weight heparin and recombinant hirudin on thrombus growth in a rabbit jugular vein thrombosis model.
    Biemond BJ; Levi M; Nurmohamed MT; Büller HR; ten Cate JW
    Thromb Haemost; 1994 Sep; 72(3):377-80. PubMed ID: 7855787
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary prevention of coronary arterial thrombosis with the factor Xa inhibitor rTAP in a canine electrolytic injury model.
    Lynch JJ; Sitko GR; Lehman ED; Vlasuk GP
    Thromb Haemost; 1995 Aug; 74(2):640-5. PubMed ID: 8585000
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant full-length tissue factor pathway inhibitor (TFPI) prevents thrombus formation and rethrombosis after lysis in a rabbit model of jugular vein thrombosis.
    Kaiser B; Fareed J
    Thromb Haemost; 1996 Oct; 76(4):615-20. PubMed ID: 8903005
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro and in vivo antithrombotic activity of PD-198961, a novel synthetic factor Xa inhibitor.
    Chi L; Peng YW; Gibson G; Hicks G; Mertz TE; Rapundalo S; Janiczek N; Edmunds JJ; Leadley R
    J Cardiovasc Pharmacol; 2004 Oct; 44(4):493-500. PubMed ID: 15454859
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antithrombotic efficacy of RPR208566, a novel factor Xa inhibitor, in a rat model of carotid artery thrombosis.
    Heran C; Morgan S; Kasiewski C; Bostwick J; Bentley R; Klein S; Chu V; Brown K; Colussi D; Czekaj M; Perrone M; Leadley R
    Eur J Pharmacol; 2000 Feb; 389(2-3):201-7. PubMed ID: 10688985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neointimal thickening after severe coronary artery injury is limited by a short-term administration of a factor Xa inhibitor. Results in a porcine model.
    Schwartz RS; Holder DJ; Holmes DR; Veinot JP; Camrud AR; Jorgenson MA; Johnson RG
    Circulation; 1996 Apr; 93(8):1542-8. PubMed ID: 8608623
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.